NC-LENOVO/FORMULA-1
10.3.2022 14:32:13 CET | Business Wire | Press release
Formula 1 and Lenovo announced today that Lenovo is an Official Partner ahead of the upcoming 2022 season. The multi-year deal will see Lenovo’s cutting-edge technology used across Formula 1’s operations as it continues to bring the highest-level of racing and entertainment to its worldwide fanbase. As global leaders in their respective fields, Formula 1 and Lenovo want to push the boundaries of what’s possible when combining sports with advanced technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005287/en/
Over the next few years, the partnership will involve Lenovo’s technology being used across the Formula 1 organization, both back at its base and at races. Lenovo’s hardware devices, as well as High Performance Computing and server solutions will be increasingly integrated throughout the organisation’s operations. From running powerful on-premises data collection solutions to producing higher quality content and supporting broadcast applications, the Formula 1 and Lenovo collaboration will result in a better experience for fans.
The partnership will drive global visibility of Lenovo, showcasing Lenovo’s capabilities on a global scale and integrating industry-leading hardware technology at the heart of Formula 1. It plans to leverage Lenovo’s extensive selection of premium hardware as well as innovative next-generation technology such as augmented and virtual reality, as F1 continues to connect fans with the sport in new and more engaging ways.
Earlier this year, F1 announced that it has extended its commitment to create employment and education opportunities for underrepresented groups, in the form of ten engineering scholarships each year through to 2025. Lenovo is also focused on diversity and inclusion and removing barriers, and through the partnership will work with F1 on projects related to this important area.
Stefano Domenicali, President & CEO of Formula 1, said:
“As we prepare for our record-breaking season, it is exciting to welcome Lenovo to the team and for us to join forces with a global leader in technology. Like everything in Formula 1, precision and detail are everything, and Lenovo will be at the forefront of providing their experience and innovative technologies to our operations throughout the season. Our fans expect the best from everything we do, and Lenovo is the perfect partner in terms of its premium hardware offerings. We are entering a new era of our sport and we’re committed to delivering a high-quality experience for our dedicated followers around the world.”
Yang Yuanqing, Chairman & CEO of Lenovo, said:
“We are proud to announce our new global partnership with Formula 1, the world’s most prestigious motor racing competition, to engage half a billion fans all over the world with exciting, innovative experiences. This partnership is based on our shared passion for innovation, performance, and the winning spirit. Together Lenovo and Formula 1 will push the limits of technology to help shape a faster, smarter, and more sustainable future.”
Luca Rossi, President of Intelligent Devices Group, Lenovo, said:
“Partnering with Formula 1 to deploy Lenovo’s smarter solutions across the organization, from base operations to the stunning excitement of the Grands Prix, will help push the boundaries of what is possible and transform the racing experience. Formula 1 is focused on its digital transformation and continuing to surprise and delight its fans. Lenovo’s portfolio of hardware, services and solutions will be key to helping Formula 1 create new ways for fans around the world to experience the same thrills you’d experience track side.”
About Formula 1®
Formula 1® racing began in 1950 and is the world’s most prestigious motor racing competition, as well as the world’s most popular annual sporting series. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: LSXMA, LSXMB, LSXMK, BATRA, BATRK, FWONA, FWONK) attributed to the Formula One Group tracking stock. The F1 logo, F1 FORMULA 1 logo, FORMULA 1, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com , and read about the latest news via our StoryHub .
LENOVO is a trademark of Lenovo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005287/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom